Graft-versus-host disease

By W. Shlomchik. Nature reviews. Immunology, 2007

2,401 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. (2011, background): “Our analysis identified 3 discordant associations with acute GVHD and NIH chronic GVHD: (1) the use of a”
Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. (2008, background): “This often fatal disease is frequently unresponsive to various immunosuppressive therapies (Lu et al., 1996; Shlomchik, 2007 ), but new approaches targeting immune modulatory molecules show great promise in treating GvHD (Jacobsohn, 2002; Tamada et al., 2000; Xu et al., 2007c).”
The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “GVHD can be rapidly lethal, with prominent immunopathology occurring in skin, gastrointestinal track, liver, lymph nodes, bone marrow, and lungs, with sparing of kidneys, muscle, and brain (Ferrara et al., 2009).”